Tracks heart problems in adults with cancer treatment
Follows cancer patients to find who risks heart damage from treatment.
Key facts
- Who runs it
- Tel-Aviv Sourasky Medical Center
- Where
- Tel Aviv, IsraelSee the site
- Trial code
- Registry title
- Evaluation and Management of Cardio Toxicity in Oncologic Patients
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 1 Aug 2016
- Expected to end
- 31 Dec 2031
- Type of study
- Observational
- Treatments tested
- ACE inhibitors
- beta blockers
- Record updated
- 2 February 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cancer who are seen in the cardio-oncology clinic at Tel Aviv Medical Center. It tracks heart problems caused by cancer treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
Main reasons for not taking part
- In the prospective study, patients who do not sign an informed consent form cannot join.
- Patients who no longer want to continue the study.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- All patient evaluated in the cardio-oncology clinic in Tel Aviv MC
Who cannot take part
- In the prospective Study - patients not sign an informed consent form
- Patient reluctance to continue the study
Where in Israel
- Tel Aviv Medical CenterTel Aviv, IsraelContact: Michal Laufer, MDTaking people
About the trial
What the trial wants to find out
The survival rate of cancer patients has greatly increased over the past decades' mainly due to early detection and the use of new medications with higher doses and combined protocols. This achievement comes with the price of cardio toxicity, leading to cardiac dysfunction ranged from transient asymptomatic left ventricular dysfunction to cardiac death. In the long term, the risk of death from cardiovascular causes exceeds that of tumor recurrence for many types of cancer. As a result of the increasing number of long-term cancer survivors the magnitude of this problem is growing. Early identification of cardio toxicity can be identified by clinical follow-up and the use of electrocardiography, cardiac biomarkers (Troponin, brain natriuretic peptide) and echocardiogram. Past studies imply that the addition of angiotensin-converting-enzyme inhibitor (ACE inhibitor) and beta blockers to the patient's treatment may prevent the development of cardiac dysfunction. However, currently there are no specific or clear guidelines for the follow-up and management of cardio-toxicity in cancer patients.
Read full original descriptionShow less
The aim of the study: To try to identify who are the patients at increased risk for developing cardio toxicity, by follow up of clinical evaluation, cardiac biomarkers and echocardiogram examination, in purpose of early diagnosis, management and prevention of cardiac events. For achieving this the investigators will build a registry which will include all the oncologic patients going an evaluation in the cardio-oncology clinic in the Tel Aviv Medical Center .
The group in the trial
- Heart failure
Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
Treatment: ACE inhibitors and beta blockers
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation and Management of Cardio Toxicity in Oncologic Patients
- Plain-language title
- Tracks heart problems in adults with cancer treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 February 2022